Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27824403 | 0.78 | EP300 (0.33) | EP300 | |
| SCHEMBL27981432 | 0.73 | GAA (0.33) | EP300 | |
| SCHEMBL27997587 | 0.73 | EP300 (0.32) | EP300 | |
| SCHEMBL7165722 | 0.73 | PIK3CA (0.46) | PIK3CAPI4KAPIK3CGPI4KBEP300 | |
| SCHEMBL19711602 | 0.72 | EP300 (0.40) | EP300 | |
| SCHEMBL27581641 | 0.72 | EP300 (0.32) | EP300 | |
| SCHEMBL17041803 | 0.68 | EP300 (0.33) | EP300ALDH1A1 | |
| SCHEMBL24229284 | 0.68 | EP300 (0.36) | EP300 | |
| SCHEMBL22855534 | 0.68 | EP300 (0.36) | EP300 | |
| SCHEMBL21999213 | 0.68 | EP300 (0.36) | EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1064402-A4 | ANTISENSE MODULATION OF LFA-3 | ISIS PHARMACEUTICALS INC (US) | 2003-06-11 | — | — | EP | disclosed |
| EP-0975654-A4 | COMPOSITION AND METHOD FOR TREATMENT OF CMV INFECTIONS | ISIS PHARMACEUTICALS INC (US) | 2002-04-10 | — | — | EP | disclosed |
| EP-1064402-A1 | ANTISENSE MODULATION OF LFA-3 | ISIS PHARMACEUTICALS, INC. (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1064403-A1 | ANTISENSE MODULATION OF PECAM-1 | ISIS PHARMACEUTICALS, INC. (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-2000059549-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK PROTEINS | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-1003916-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK PROTEINS | ISIS PHARMACEUTICALS, INC. (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-0975654-A1 | COMPOSITION AND METHOD FOR TREATMENT OF CMV INFECTIONS | ISIS PHARMACEUTICALS, INC. (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999047707-A1 | ANTISENSE MODULATION OF LFA-3 | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1999047708-A1 | ANTISENSE MODULATION OF PECAM-1 | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1999009214-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK PROTEINS | ISIS PHARMACEUTICALS, INC. (US) | 1999-02-25 | — | — | WO | disclosed |
| WO-1998045314-A1 | COMPOSITION AND METHOD FOR TREATMENT OF CMV INFECTIONS | ISIS PHARMACEUTICALS, INC. (US) | 1998-10-15 | — | — | WO | disclosed |